MHRA — authorised 30 May 2020
- Marketing authorisation holder: Sanofi-Aventis groupe
- Status: approved
🇬🇧 Hu38Sb19 in United Kingdom
MHRA authorised Hu38Sb19 on 30 May 2020
Marketing authorisation
Hu38Sb19 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Hu38Sb19 approved in United Kingdom?
Yes. MHRA authorised it on 30 May 2020.
Who is the marketing authorisation holder for Hu38Sb19 in United Kingdom?
Sanofi-Aventis groupe holds the UK marketing authorisation.